Trial Profile
Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs INO 4212 (Primary) ; INO 4212 (Primary) ; INO 9012; INO 9012
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals
- 21 Mar 2019 Results presented in an Inovio Pharmaceuticals media release.
- 19 Mar 2019 Results published in the Journal of Infectious Diseases
- 12 Mar 2019 According to Inovio Pharmaceuticals media release, Inovio expects to have clinical data from several Phase 1 vaccine programs published multiple publications in 2019: Ebola vaccine; MERS vaccine; HIV; and ZIka vaccine study in Puerto Rico.